Back to search
FDAFDA · Food and drugs·Recall number Z-0789-2014

TRUFILL® n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic System: One 1 g tube of n-BCA, one 10 mL vial of Ethiodized Oil and one 1 g vial of Tantalum Powder Product Code: 631-500 The TRUFILL n-BCA Liquid Embolic System is indicated for the embolization of cerebral arteriovenous malformations (AVMs) when pre-surgical devascularization is desired. The system is used under fluoroscopic guidance to obstruct or reduce blood flow to cerebral arteriovenous malformations (AVMs) via superselective catheter delivery.

Published January 29, 2014 · Recall initiated: October 11, 2013

Summary

FDA records medical device Class I recall Z-0789-2014, published January 29, 2014 and initiated October 11, 2013. Recalling firm: Codman & Shurtleff, Inc.; Status: Terminated; Reported quantity: 7,983; Lot: All lot codes. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Incorrect instructions for use (IFU).

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Codman & Shurtleff, Inc.
Distributor
Worldwide Distribution: US (nationwide) including Puerto Rico; and internationally to: Costa Rica and Russia.
Lot
All lot codes
Risk classification
Class I
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was TRUFILL® n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic System: One 1 g tube of n-BCA, one 10 mL vial of Ethiodized Oil and one 1 g vial of Tantalum Powder Product Code: 631-500 The TRUFILL n-BCA Liquid Embolic System is indicated for the embolization of cerebral arteriovenous malformations (AVMs) when pre-surgical devascularization is desired. The system is used under fluoroscopic guidance to obstruct or reduce blood flow to cerebral arteriovenous malformations (AVMs) via superselective catheter delivery. recalled?

Yes. FDA published recall Z-0789-2014 on January 29, 2014. Reported hazard: Incorrect instructions for use (IFU).

What should I do if I have this product?

Voluntary: Firm initiated · Letter